Company Profile
Tempest Therapeutics Stock Price, News & Catalysts
- Ticker:
- TPST
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.90 USD (-26.03%)
Close
Last updated: September 17, 2026
19.4M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, TPST closed down 26.0% at $0.8950. No new same-company headline was identified in the current news window.
Company overview
In Vivo CAR T Company
Tempest Therapeutics develops next-generation CAR T therapies for autoimmune diseases and cancer. Its platform is designed to generate therapeutic CAR T cells directly inside the body using targeted mRNA and lipid nanoparticles.
CD7-Targeted Delivery
Tempest's proprietary delivery system targets CD7-positive T cells with an mRNA/LNP payload. This approach is intended to avoid ex vivo manufacturing and make immune-reset treatment more broadly accessible.
TPST-4003
TPST-4003 combines the in vivo delivery platform with a dual CD19/BCMA CAR construct to drive broad B-cell-lineage depletion and immune reset. Initial development targets myasthenia gravis and multiple sclerosis through a partner-led investigator study in China.
TPST-2003
TPST-2003 is an ex vivo dual CD19/BCMA CAR T therapy in development for relapsed or refractory multiple myeloma, including patients with extramedullary disease. Tempest is preparing a potentially registrational clinical study.
Future catalysts
- First patient enrollment and dosing with TPST-4003 in the fourth quarter of 2026.
- Initiation of a potentially registrational TPST-2003 study in relapsed or refractory multiple myeloma in 2026.
- Initial clinical data from the TPST-4003 investigator study in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Tempest Therapeutics (TPST)?
Tempest Therapeutics (TPST) most recently closed at 0.90 USD, a -26.03% move versus the previous session.
What is the market cap of Tempest Therapeutics (TPST)?
Tempest Therapeutics currently has a market capitalization of 19.4M USD on BioPharmSignal.
What does Tempest Therapeutics do?
In Vivo CAR T Company Tempest Therapeutics develops next-generation CAR T therapies for autoimmune diseases and cancer. Its platform is designed to generate therapeutic CAR T cells directly inside the body using targeted mRNA and lipid nanoparticles. CD7-Targeted Delivery Tempest's proprietary delivery system targets CD7-positive T cells with an mRNA/LNP...
On which exchange is TPST stock listed?
Tempest Therapeutics (TPST) is associated with NASDAQ, United States, Biopharma.
What is TPST-4003?
First patient enrollment and dosing with TPST-4003 in the fourth quarter of 2026.
Which conditions is Tempest Therapeutics targeting with TPST-4003?
Tempest Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Tempest Therapeutics describe recent progress with TPST-4003?
First patient enrollment and dosing with TPST-4003 in the fourth quarter of 2026.
What is TPST-2003?
TPST-2003 TPST-2003 is an ex vivo dual CD19/BCMA CAR T therapy in development for relapsed or refractory multiple myeloma, including patients with extramedullary disease.